Nonvalvular atrial fibrillation
Conditions
Interventions
Edoxaban tosilate hydrate OD tablets 30 mg without water.
Edoxaban tosilate hydrate OD tablets 60 mg without water.
Edoxaban tosilate hydrate OD tablets 30 mg with water.
Edoxaban tosilate hydrate OD
Sponsors
Daiichi Sankyo Co., Ltd. Medical Science Department
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who are 20 years of age or older at the time of informed consent. 2) Patients who have been taking 30mg or 60mg of edoxaban tablets for more than 2 weeks before obtaining informed consent. 3) Patients who provided voluntary consent to participate in the study after receiving sufficient explanation.
Exclusion criteria
Exclusion criteria: 1)Patients who are taking dual anti-platelet therapy. 2)Patients who have experienced any cardiovascular events (stroke, myocardial infarction, cardiac intervention for cardiac events other than myocardial infarction, or heart failure requiring hospitalization) or any bleeding leading to hospitalization within two weeks before enrollment. 3) Patients who are pregnant or breast-feeding, or who have possibility to be pregnant. 4) Patients who are judged unsuitable for this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of sensory | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of safety | — |
Countries
Japan
Contacts
Public ContactJun Okada
EP-CRSU Co., Ltd. Clinical Research Project Division Research Promotion Dept.
Outcome results
None listed